GlassScriptPhysician profile
Shona J Quick
NPI 1033308820
$3,368.59
in general payments reported to CMS, 2019-2025
25 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,872 · 2022: $808 · 2023: $116 · 2024: $118 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $782.60 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $542.85 | 2021-2022 | |
| Janssen Biotech, INC. | $317.61 | 2021-2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $305.63 | 2021-2023 | Linzess |
| Gilead Sciences, INC. | $274.39 | 2021-2024 | Livdelzi |
| Janssen Scientific Affairs, LLC | $175.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.85 | 2021-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $137.91 | 2021-2022 | |
| Redhill Biopharma INC. | $99.47 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $83.25 | 2021 | |
| Pfizer INC. | $76.59 | 2021 | |
| Celgene Corporation | $66.22 | 2021-2022 | |
| Amgen INC. | $49.63 | 2022-2023 | Prolia, Evenity |
| Lilly USA, LLC | $48.63 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $46.59 | 2024-2025 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $34.17 | 2021-2023 | Sutab |
| Nestle Healthcare Nutrition INC. | $28.81 | 2021 | |
| Qol Medical, LLC | $27.53 | 2021 | |
| Ethicon US, LLC | $24.38 | 2021 | |
| Novo Nordisk INC | $19.96 | 2025 | Wegovy |
| Ardelyx, INC. | $19.77 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $15.52 | 2025 | Trelegy Ellipta |
| Grifols USA, LLC | $14.59 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.49 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shona Quick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.